Skip to content

Nasopharyngeal Bacterial Carriage and Antibiotic Resistance in Children With Sickle Cell Disease in Ile-De-France

Nasopharyngeal Bacterial Carriage and Antibiotic Resistance in Children With Sickle Cell Disease in Ile-De-France

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05197205
Acronym
DREPANO-BACT
Enrollment
600
Registered
2022-01-19
Start date
2022-02-01
Completion date
2023-02-01
Last updated
2022-01-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sickle Cell Disease

Keywords

Sickle celle disease, Nasopharyngeal bacterial carriage

Brief summary

The objective of this study is to to determine the rate of nasopharyngeal carriage of Streptococcus pneumoniae (Sp) in children with sickle cell disease over 6 months and under 15 years of age over a 9-month period in Ile-De-France.

Detailed description

Sickle cell disease is the most common genetic disease in France, with one affected child for every 1,736 births. Ile-de-France is the region in Europe with the highest prevalence of sickle cell disease. Children with sickle cell disease have an increased susceptibility to infections related to encapsulated bacteria and are at high risk of invasive infections (particularly Streptococcus pneumoniae), which is the leading cause of mortality in children with sickle cell disease under 5 years of age worldwide. the patients are subject to intense selection pressure (long-term antibiotic prophylaxis and systematic probabilistic curative antibiotic therapy) and are at high risk of carrying nosocomial bacteria (repeated hospitalizations). Moreover, children with sickle cell disease have reinforced immunization schedules, especially against pneumococcal disease. However, data concerning the carriage of resistant bacteria (prevalence, risk factors) in children with sickle cell disease in France are scarce. This study aims to determine the nasopharyngeal bacterial carriage and antibiotic resistance in children with sickle cell disease in Ile-De-France

Interventions

PROCEDUREnasopharyngeal swabbing

A nasopharyngeal swab is collected during the consultation, with bacteriological analysis. No follow-up visit is required for this study

Sponsors

Assistance Publique - Hôpitaux de Paris
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SCREENING
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
6 Months to 15 Years
Healthy volunteers
Yes

Inclusion criteria

* Children aged 6 months to 15 years, regardless of immunization status. * Child with a major sickle cell syndrome (SS, SC, S+, S°, SE) followed in one of the centers of competence or reference for rare diseases (CRMR) Major sickle cell syndromes, Thalassemias and other rare pathologies of the Red Blood Cell and Erythropoiesis in Ile de France. * Children who are not subject to legal protection measures. * Child affiliated to a social security system. * Signed informed consent

Exclusion criteria

* Sickle cell child with a febrile syndrome at the time of sampling or hospitalized for any reason. * Child having received antibiotic therapy other than oracillin in the 7 days preceding the nasopharyngeal swab. * Child already included in the observation period (only 1 nasopharyngeal swab per patient). * Other hemoglobinopathies and heterozygous AS or AC patients. * Patients already involved in a therapeutic protocol or in the exclusion period following a previous research. * Patients under AME or without social security coverage.

Design outcomes

Primary

MeasureTime frameDescription
determine the proportion of sickle cell children with nasopharyngeal carriage of Streptococcus pneumoniae (Sp) among the total number of sickle cell children screened by nasopharyngeal swab.12 monthsthe rate of nasopharyngeal carriage of Streptococcus pneumoniae (Sp) in children with sickle cell disease aged over 6 months and under 15 years over a 12-month period in Ile-De-France.

Secondary

MeasureTime frameDescription
determine the rate of nasopharyngeal carriage of penicillin-deficient pneumococcus (PDSP) in sickle cell children over 6 months and under 15 years of age over a 9-month period in Ile-De-France.12 monthsProportion of sickle cell children with nasopharyngeal carriage of penicillin-deficient pneumococcus (PDSP) among the total number of sickle cell children screened by nasopharyngeal swab.
determine the proportion of vaccine serotypes among pneumococcal strains in children with sickle cell disease aged over 6 months and under 1512 monthsProportion of children with vaccine serotypes among the pneumococcal strains
Determine the proportion of non-vaccine serotypes among all pneumococcal strains in children with sickle cell disease over 6 months and under 15 years of age.12 monthsProportion of non-vaccine serotypes among all pneumococcal strains.
Determine the nasopharyngeal carriage rate of methicillin-resistant Staphylococcus aureus (MRSA), Haemophilus influenzae, Moraxella catarrhalis in children with sickle cell disease over 6 months and under 15 years of age.12 monthsProportion of children with MRSA, Haemophilus influenzae, Moraxella Catarrhalis (isolated from a nasopharyngeal swab).
compare the rate of nasopharyngeal carriage of Streptococcus pneumoniae and PSDP between the sickle cell group and the healthy group of children according to age groups.12 monthsProportion of children with Streptococcus pneumoniae and PSDP (isolated on nasopharyngeal swab) by age group.
Compare the proportion of non-vaccine serotypes among the Streptococcus pneumoniae strains between the sickle cell group and the healthy group of children.12 monthsProportion of non-vaccine serotypes among nasopharyngeal strains of Streptococcus pneumoniae.
compare the nasopharyngeal carriage rate of MRSA, Haemophilus influenzae, Moraxella catarrhalis between the sickle cell group and the healthy children group.12 monthsProportion of children with MRSA, Haemophilus influenzae, Moraxella Catarrhalis (isolated on nasopharyngeal swab).

Contacts

Primary ContactLuu-Ly PHAM
luu-ly.pham@aphp.fr0148024405
Backup ContactHOUDA ALLALOU
houda.allalou@aphp.fr0148957407

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026